COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The COVID-19 pandemic has brought challenges for people with rheumatic disease in addition to those faced by the general population, including concerns about higher risks of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and poor outcomes of COVID-19. The data that are now available suggest that rheumatic disease is associated with a small additional risk of SARS-CoV-2 infection, and that outcomes of COVID-19 are primarily influenced by comorbidities and particular disease states or treatments. Despite considerable advances in our knowledge of which therapeutic agents provide benefits in COVID-19, and of what constitutes effective vaccination strategies, the specific considerations that apply to people with rheumatic disease are yet to be definitively addressed. An overview of the most important COVID-19 studies to date that relate to people with rheumatic disease can contribute to our understanding of the clinical-care requirements of this population. In this Review, the authors summarize the current knowledge relating to SARS-CoV-2 infection and the prevention and treatment of COVID-19 in people with rheumatic disease. People with immune or inflammatory rheumatic disease might have a higher risk of infection with SARS-CoV-2 after exposure than the general population, although the additional risk is probably small. Risk of poor COVID-19 outcomes in patients with rheumatic disease seems to be mediated by the presence of comorbidities, treatment with glucocorticoids or rituximab, and high disease activity. People with immune or inflammatory rheumatic disease who experience mild COVID-19 symptoms should stop taking immunomodulating medications for 1–3 weeks from the onset of disease. People with rheumatic disease with positive SARS-CoV-2 test results or mild COVID-19 symptoms and risk factors for poor outcomes should stop taking immunomodulating medications and consider treatment with antiviral medications. Most patients with treated rheumatic disease generate antibody responses to SARS-CoV-2 vaccines, but medications such as B cell-depleting therapies and mycophenolate confer a high risk of poor responses. People with immune or inflammatory rheumatic disease are strongly recommended to receive SARS-CoV-2 vaccination, including booster doses if recommended, despite some evidence of a diminished response in particular groups. People with immune or inflammatory rheumatic disease might have a higher risk of infection with SARS-CoV-2 after exposure than the general population, although the additional risk is probably small. Risk of poor COVID-19 outcomes in patients with rheumatic disease seems to be mediated by the presence of comorbidities, treatment with glucocorticoids or rituximab, and high disease activity. People with immune or inflammatory rheumatic disease who experience mild COVID-19 symptoms should stop taking immunomodulating medications for 1–3 weeks from the onset of disease. People with rheumatic disease with positive SARS-CoV-2 test results or mild COVID-19 symptoms and risk factors for poor outcomes should stop taking immunomodulating medications and consider treatment with antiviral medications. Most patients with treated rheumatic disease generate antibody responses to SARS-CoV-2 vaccines, but medications such as B cell-depleting therapies and mycophenolate confer a high risk of poor responses. People with immune or inflammatory rheumatic disease are strongly recommended to receive SARS-CoV-2 vaccination, including booster doses if recommended, despite some evidence of a diminished response in particular groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674 · cited 1×
“USA RA (33,886) Individuals without RA (33,886) HR 1.”
BackgroundmRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“South Korea Inflammatory arthritis, CTD with PCR test (8,297) General population with PCR test (133,609) NR OR 1.”
BackgroundVoysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Metadata
- Authors
- Grainger, R., Kim, A. H. J., Conway, R., Yazdany, J., & Robinson, P. C.
- Venue
- Nature Reviews Rheumatology
- Published
- 2022-02-25
- Volume
- 18
- Issue
- 4
- Pages
- 191-204
- ISSN
- 1759-4790 (ISSN-L)
- 1759-4804
- OpenAlex
- W4214501619
- Cited by
- 188
- References
- 30
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. https://app.cochat.ai/papers/10.1038/s41584-022-00755-x
- The paper
- Grainger, R., Kim, A. H. J., Conway, R., Yazdany, J., & Robinson, P. C. (2022). COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-022-00755-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.